drugset
drugset / Trial / NCT04233060

A Study of CS3005 in Advanced Solid Tumors

NCT04233060 ↗

Phase 1 Completed 9 enrolled CStone Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects with Advanced Solid Tumors

Timeline

Start
2020-01-10
Primary completion
2021-01-31
Completion
2021-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject CS3005 Unknown — Oral

Indications

neoplasm